Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
D. Petrylak,C. Tangen,11 Authors,E. Crawford
2004 · DOI: 10.1056/NEJMOA041318
New England Journal of Medicine · 3,741 Citations
TLDR
The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.